ESR1 and breast carcinoma: Over the past several years, new methods of inhibiting estrogen action have been incorporated into the treatment of ER+ breast cancer, including the use of pharmaceutical agents that block ovarian suppression and the development of ER degraders such as SERDs with improved bioavailability.